Moderna, Inc. (MRNA) News
Follow Moderna, Inc. (MRNA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 157 public stories across 49 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
OpenAI Launches Biology AI, Restricts Access to Approved Labs
OpenAI launched an AI for biology that answers more high-risk queries and will make it available only to approved laboratories.
EQUITY | Nov 01, 2026, 04:33 AM UTC
M
Moderna CEO Defends Cancer Vaccine After Stock Falls on Data Leak
Moderna CEO Stéphane Bancel said investors should focus on the science after the company's shares fell following a data leak involving its cancer-vaccine candidate.
EQUITY | Oct 26, 2026, 10:23 PM UTC
M
New York Stocks Open Higher as Oil Eases Ahead of Fed Decision
New York stocks opened higher as oil eased, with investors awaiting the Federal Reserve's decision.
EQUITY | Oct 26, 2026, 03:42 PM UTC
M
Moderna shares fall 6.4%
Moderna shares fell 6.4% after Citi maintained its bearish rating following the release of complete melanoma vaccine data.
EQUITY | Oct 26, 2026, 03:06 PM UTC
M
Moderna shares pare losses, last down 6.4%
EQUITY | Oct 26, 2026, 01:45 PM UTC
M
Moderna Shares Fall 9.3% Premarket After Two-Session Drop
Moderna shares are down 9.3% premarket after falling over 18% in the previous two sessions.
EQUITY | Oct 26, 2026, 10:36 AM UTC
M
Moderna Shares Fall Nearly 18% as Vaccine Rally Falters
Moderna shares plunged nearly 18% to close at $202.63 on Thursday. Mizuho analyst Jared Holz called the stock a “do-not-trade” for many investors because of extreme volatility.
EQUITY | Oct 23, 2026, 01:29 AM UTC
M
Moderna Shares Plunge 18% After Melanoma Vaccine Data Leak
Moderna shares fell about 18% after leaked trial data for its melanoma vaccine fell short of elevated Wall Street expectations. The data had been slated for announcement over the weekend.
EQUITY | Oct 22, 2026, 09:11 PM UTC
M
US Stocks Finish Mixed as Nasdaq Falls on AI Concerns
Stocks finished mixed, with artificial-intelligence worries weighing on the Nasdaq while earnings buoyed the Dow. Treasury yields fell as bond prices rose, and the dollar slipped against the yen.
EQUITY | Oct 22, 2026, 08:41 PM UTC
M
Merck, Moderna Phase 3 Combo Cuts Melanoma Recurrence Risk 42%
Merck said intismeran (V940) plus KEYTRUDA reduced recurrence or death risk by 42% and distant metastasis or death risk by 38% versus KEYTRUDA alone in resected stage IIB–IV melanoma. Overall survival data are not mature
EQUITY | Oct 22, 2026, 07:00 PM UTC
M
Merck and Moderna Report Positive Phase 3 INTerpath-001 Trial Results
Merck and Moderna announced positive recurrence-free and distant metastasis-free survival results for intismeran autogene plus Keytruda in the Phase 3 INTerpath-001 trial.
EQUITY | Oct 22, 2026, 06:59 PM UTC
M
Moderna Shares Fall About 25% After Cancer-Vaccine Data Leak
Moderna shares fell around 25% after details from a closely guarded mRNA cancer-vaccine study were shared on social media, putting the stock on pace for its largest decline since the company went public.
EQUITY | Oct 22, 2026, 06:52 PM UTC
M
Merck-Moderna Vaccine Cuts Melanoma Death or Recurrence Risk 42%
Trial data show the mRNA vaccine, combined with a widely used immunotherapy, cut melanoma disease-spread risk by 38%.
EQUITY | Oct 22, 2026, 06:25 PM UTC
M
Moderna Shares Plunge Around 25% After Cancer-Vaccine Data Leak
Details from a closely guarded mRNA-based cancer-vaccine study were shared on social media. Moderna shares fell around 25%, putting the stock on pace for its largest decline since going public.
EQUITY | Oct 22, 2026, 06:09 PM UTC
M
Moderna Shares Hit 52-Week High as Goldman Raises Price Target
Moderna shares rose sharply on Thursday and reached a fresh 52-week high after Goldman Sachs raised its price target. The move came ahead of full trial data for the company’s cancer vaccine.
EQUITY | Oct 15, 2026, 07:43 PM UTC
M
Nike, Moderna and Walmart Rise as Investors Rotate From AI Stocks
Nike, Moderna and Walmart shares climbed Thursday as investors shifted out of technology and AI stocks for a second session. AI infrastructure shares fell, with Dell down more than 9% and Broadcom down 2.5% early Thursda
EQUITY | Oct 15, 2026, 06:15 PM UTC
M
Moderna to report third-quarter 2026 results November 6
Moderna said it will report third-quarter 2026 financial results on Friday, November 6, 2026.
EQUITY | Oct 13, 2026, 11:00 AM UTC
M
Moderna Shares Gain 18% in a Week, Reach Four-Year High
Moderna shares rose 18% last week, finishing at their highest level in more than four years. The move followed a New York Times report that the NIH is planning a public-private effort to speed up cancer vaccines.
EQUITY | Oct 12, 2026, 01:05 PM UTC
H
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Author Stephen King has criticized President Donald Trump’s new White House press secretary, Katie Zacharia, over her past social media posts promoting vaccine-related claims, questioning the 2020 election results and al
LIVE | Oct 12, 2026, 09:12 AM UTC
H
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh investor interest in vaccine makers, sending several biotechnology and pharmaceutical stocks higher Friday. Moderna, Inc. (NA
LIVE | Oct 09, 2026, 07:11 PM UTC
H
Stock Market Today: Nasdaq 100 Rebounds From OpenAI Scare, T-Mobile Tumbles 12%
U.S. stocks edged higher by midday Friday, with the Nasdaq rebounding from Thursday’s setback sparked by concerns over OpenAI’s weaker-than-expected revenue, while the wireless carriers were hammered by a Space Explorati
LIVE | Oct 09, 2026, 05:27 PM UTC
H
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday. Shares of Humana Inc (NYSE: HUM ) rose sharply after the company said Friday that its 2027 Medicare Advantage Star Ratings improved
LIVE | Oct 09, 2026, 02:51 PM UTC
M
Moderna Shares Surge As Nasdaq-100 Re-Entry Looms
Moderna (MRNA) shares climbed approximately 7% on Monday, nearing $204, as investors anticipate the company's return to the Nasdaq-100 index later this week. The stock has seen a year-long surge.
EQUITY | Oct 05, 2026, 07:30 PM UTC
H
Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today
U.S. stocks are higher at midday Wednesday, led by technology and software shares, after softer-than-expected inflation data eased fears of another Federal Reserve rate hike. Oil is climbing again, however, and long-date
LIVE | Sep 30, 2026, 04:47 PM UTC
H
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum
Moderna Inc. (MRNA) shares fell about 6% in premarket trading Wednesday after Citi downgraded the biotech stock from Neutral to Sell, saying its valuation has run ahead of expected revenue and earnings after a sharp 2026
EARNINGS | Sep 30, 2026, 12:03 PM UTC
H
Concentrix Posts Mixed Q3 Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.2% on Wednesday. Shares of Concentrix Corporation (NASDAQ: CNXC ) fell sharply in pre-market trading after the company reported mixed thir
LIVE | Sep 30, 2026, 12:02 PM UTC
L
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell. — Barrons.com
By Mackenzie TatananniModerna's eye-watering rally has officially outpaced its fundamentals, according to one analyst, prompting a downgrade at a major Wall Street firm.Citi's Geoff Meacham cut his rating on Moderna shar
EQUITY | Sep 30, 2026, 11:42 AM UTC
L
Moderna appoints Juan Andres as COO; Jerh Collins to retire
Moderna appointed Juan Andres as Chief Operating Officer, effective October 5, 2026, and announced the retirement of Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer.Original SEC Filing: Moderna, Inc.
REGULATION | Sep 30, 2026, 11:23 AM UTC
L
Moderna, Inc. (MRNA) Appoints Juan Andres as COO; Collins Retires
Moderna added a Chief Operating Officer role and named Juan Andres as COO effective Oct. 5, 2026; Jerh Collins, Chief Technical Operations and Quality Officer, will retire.Material DetailsContext by AI AnalystThis is a m
NEWS | Sep 30, 2026, 11:08 AM UTC
L
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at ModernaCAMBRIDGE, MA / / September 30, 2026 / Moderna, Inc. NASDAQ:MRNA today announced the addition
NEWS | Sep 30, 2026, 11:08 AM UTC
L
Moderna Price Target Raised to $80.00/Share From $60.00 by Citigroup
Ratings actions from Benzinga: GMT) Moderna Cut to Sell From Neutral by CitigroupRatings actions from Benzinga
NEWS | Sep 30, 2026, 10:32 AM UTC
L
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
By Blake BrittainA federal judge in Delaware on Monday rejected Pfizer NYSE:PFE, BioNTech NASDAQ:BNTX and Moderna's NASDAQ:MRNA requests to dismiss patent lawsuits filed against them by Bayer's XETR:BAYN Monsanto unit ov
REGULATION | Sep 28, 2026, 06:20 PM UTC
L
Weekly Recap: Intismeran Phase III success and FDA approval of mFLU
Moderna, Inc. (NASDAQ:MRNA) is pivoting from COVID to a broad mRNA platform—winning FDA approval for mFLU, reporting strong Phase III Intismeran results that accelerate vaccine, oncology and rare—disease programs, and sc
REGULATION | Sep 28, 2026, 11:05 AM UTC
L
MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data
Shares of Moderna (MRNA) are on track for their best year on record as investors await detailed melanoma trial results, while an analyst said that China leads the U.S. in AI-driven drug development lack credible evidence
GEOPOLITICS | Sep 28, 2026, 07:59 AM UTC
L
Why Did AMD, HPE, MRNA Stocks Surge To 52-Week Highs Last Week?
Advanced Micro Devices (AMD), Hewlett Packard Enterprise (HPE) and Moderna (MRNA) surged to fresh 52-week highs Friday as investors piled into AI infrastructure, enterprise computing and biotechnology growth stories. AMD
NEWS | Sep 28, 2026, 04:48 AM UTC
H
Innovation Is Driving A New Bull Market In Biotech. 16 Picks. — Barron's
Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.By Lauren R. RublinA tidal wave of innovation in biotechnolog
MNA | Sep 26, 2026, 01:37 AM UTC
H
AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street
Wall Street closed the week riding a semiconductor rebound that pushed the AI infrastructure trade back into favor, even as a spike in Treasury yields tested the rally’s staying power. Advanced Micro Devices Inc. (NASDAQ
LIVE | Sep 25, 2026, 08:02 PM UTC
L
MRNA, PGEN Stocks Hit Multi-Year Highs — What’s Driving The Momentum Today?
Moderna (MRNA) and Precigen (PGEN) hit new milestones on Friday, as investors weighed fresh Wall Street commentary on the biotech companies’ cancer-focused therapies.MRNA shares gained 1.5% to their highest level since J
EQUITY | Sep 25, 2026, 06:37 PM UTC
H
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. — Barrons.com
Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.By Lauren R. RublinA tidal wave of innovation in biotechnolog
MNA | Sep 25, 2026, 03:40 PM UTC
L
Money Quote: Moderna CEO — WSJ
"The thing I'm most worried about right now is actually bioterrorism."-Moderna CEO Stéphane Bancel, speaking about the risks that AI poses at Journal House yesterday. He said he sees a scenario in which a bad actor uses
NEWS | Sep 25, 2026, 11:05 AM UTC
L
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Moderna, Inc. (MRNA) is on track to become September’s second-best performer in the S&P 500, but five smaller stocks have delivered even larger gains this month, driven by developments ranging from an impending ALS trial
EQUITY | Sep 25, 2026, 03:24 AM UTC
L
From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done
Shares of Moderna (MRNA) extended a two-month surge on Thursday, helped most recently by CEO Stéphane Bancel’s optimism about the company’s potential outside of COVID vaccines and backed by positive late-stage trial resu
EQUITY | Sep 24, 2026, 10:41 PM UTC
L
Biotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMN
SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 23, 2026, driven by key catalysts such as positive quarterly reports or results from clinical trials.Alpha Teknova Inc. (TKNO)Alpha T
NEWS | Sep 24, 2026, 09:42 AM UTC
L
Why Did META, MRNA, OKTA Stocks Surge To 52-Week Highs Today?
Shares of Meta Platforms Inc. (META), Moderna Inc. (MRNA), and Okta Inc. (OKTA) rallied to fresh 52-week highs on Wednesday as new launches, positive management commentary, and rising investor optimism bolstered them hig
EQUITY | Sep 24, 2026, 03:53 AM UTC
L
These 2 Stocks Are Bucking The Broader Market Selloff To Hit New Multi-Year Highs — Here’s What’s Driving The Enthusiasm
Moderna (MRNA) and Twilio (TWLO) defied the broader market selloff on Wednesday to hit new milestones, as investors cheered Moderna’s growing mRNA opportunities beyond COVID-19 vaccines and Twilio’s potential to benefit
NEWS | Sep 23, 2026, 05:55 PM UTC
M
Moderna shares jump as intismeran autogene nears next test
Moderna said it will present three abstracts on intismeran autogene, its personalized mRNA cancer vaccine, ahead of its next major test.
EQUITY | Sep 21, 2026, 05:14 PM UTC
H
MRNA - Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
MRNA - Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
GEOPOLITICS | Sep 21, 2026, 02:12 PM UTC
H
Bulls and Bears: Generac, Salesforce, Netflix
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks finished a volatile week with mixed results as investors adjusted to the Federal Reser
LIVE | Sep 19, 2026, 12:00 PM UTC
H
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04, the S&P 500 advancing 1.14% to 7,637.76 and the Nasdaq climbing 1.69% to 26,418.29. These are the top stocks
LIVE | Sep 18, 2026, 01:19 AM UTC
H
Moderna jumps on personalized mRNA Phase 3 success; raises $2.96B via 0% notes
Moderna surged on Phase 3 success for a personalized mRNA cancer vaccine with Keytruda in resected stage IIB–IV melanoma. The company also raised about $2.96B through 0% convertible notes due 2032 with capped calls.
EQUITY | Sep 07, 2026, 11:22 AM UTC
L
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels - Heard on the Street — WSJ
By David WainerThe excitement surrounding Moderna and Merck's personalized mRNA cancer vaccine added more than $50 billion in combined market value for the two drug companies. But it is also creating a gold rush in a gro
COMMODITIES | Sep 04, 2026, 09:30 AM UTC
M
Moderna shares fall after Rothschild & Co Redburn downgrade to Sell
Moderna shares fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns.
EQUITY | Sep 03, 2026, 07:45 PM UTC
L
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense — Barrons.com
By Paul R. La MonicaWant a prescription for investing success? Check out Big Pharma companies, biotechs, and other healthcare stocks.The healthcare sector has been on a hot streak, trouncing the broader market, and there
EQUITY | Sep 03, 2026, 05:40 PM UTC
L
Rothschild cuts Moderna to Sell from Neutral, analyst note
Rothschild & Co analyst Simon Baker cut Moderna from Neutral to Sell in a research note Thursday, marking the company’s second Sell rating. The downgrade was described as having little link to commercial potential or pip
EQUITY | Sep 03, 2026, 03:10 PM UTC
M
Moderna cut to sell from neutral by Rothschild & Co
Rothschild & Co downgraded Moderna to sell from neutral and raised its price target to $81.00 a share from $40.00.
EQUITY | Sep 03, 2026, 12:01 PM UTC
L
Moderna shares slip Wednesday amid yield pressures and recent financing
Moderna (MRNA) is lower Wednesday morning, down 3.07% to $149.54 at publication. The move comes after a trailing-month 170% surge alongside a recently closed $2.6 billion convertible notes deal as benchmark yields remain
RATES | Sep 02, 2026, 02:42 PM UTC
M
Moderna completes $3.0B convertible notes offering due 2032
Moderna completed a $3.0 billion private offering of 0.00% Convertible Senior Notes due March 1, 2032 and executed the related indenture. Notes are convertible at $210.58 per share, with settlement in cash, stock, or com
EQUITY | Sep 01, 2026, 08:44 PM UTC
L
Moderna announces investor-conference participation in September 2026
Moderna said it will participate in upcoming investor conferences in September 2026. A live webcast of the presentations will be available under “Events and Presentations” in the Investors section.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
MRNA - Moderna to Present at Upcoming Conferences in September 2026
MRNA - Moderna to Present at Upcoming Conferences in September 2026
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Moderna leads S&P 500 in August; Edison International sinks
Moderna led the S&P 500 in August while Edison International sank, according to Barrons.com.
EQUITY | Aug 31, 2026, 04:51 PM UTC